Brittle Addison’s disease: a new variation on a familiar theme

Geoffrey V Gill, Gareth Williams

Summary

Unstable and unpredictable disease control in diabetes or asthma, with frequent hospitalisations, is frequently referred to as ‘brittle’. We describe two cases of Addison’s disease with recurrent hospitalisations in hypo-adrenal crises. Both patients had significant psychosocial disruption, and failure to take hydrocortisone replacement therapy was admitted in one and biochemically proven in the other. We propose that ‘brittle’ Addison’s disease in these cases was due to poor treatment compliance related to psychosocial factors. These features have particular similarities with the syndrome of brittle diabetes.

Keywords: Addison’s disease; hypo-adrenalism; diabetes; asthma

The term ‘brittle’ diabetes has long been used to refer to a small sub-group of insulin-dependent (Type 1) diabetic patients who suffer life-disrupting glycaemic instability associated with multiple or prolonged hospital admissions. The term has also been applied to asthma, describing unpredictable severe declines in respiratory function, also with frequent hospitalisations. We describe here two patients with Addison’s disease who have had repeated admissions with hypo-adrenal crises, and who we believe could be considered to have brittle Addison’s disease.

Case histories

Case 1

A 23-year-old woman had polyglandular autoimmune failure comprising Addison’s disease (of 8 years duration), hypoparathyroidism and primary ovarian failure. She was treated with hydrocortisone, alfalcacidol and oestrogen replacement. Between 1992 and 1997 she was admitted nine times with acute Addisonian crises, and on each occasion responded promptly to intravenous saline and hydrocortisone. At clinic visits in between she was consistently hypocalcaemic (eg, Ca 1.43 mmol/l with positive Trousseau’s and Chvostek’s signs). She was also hyperpigmented, frequently had low random plasma cortisol levels, and was often hypotensive. Hydrocortisone dosage was increased to 60 mg/day (2–3 times the usual replacement dose), calcium and then magnesium supplements were added, and alfalcacidol was increased to 6 µg daily (several times the usual treatment dose). During two of her admissions she was found to have urinary tract infections, but no other precipitants were found. Two of the episodes were life-threatening. After 1996, however, admissions ceased, and she admitted subsequently that she had taken her tablets only intermittently, depositing most of them in the tank of her pet goldfish (who was apparently unharmed by these ambient electrolyte insults). She came from a broken family, and her father had been violent and had abused alcohol. Apart from one admission coinciding with school exams, however, there was no clear relationship of hospitalisations to life crises, though this was rarely enquired into. Interestingly, though hypo-adrenal problems have ceased, hypocalcaemia persists despite large doses of both alfalcacidol and calcium.

Case 2

A 34-year-old woman was admitted in severe Addisonian crisis. Plasma Na was 126 mmol/l, plasma K 5.9 mmol/l, plasma urea 14.6 mmol/l, and plasma cortisol 20 nmol/l with no response to intramuscular tetracosactrin (Synacthen). Adrenal antibodies were positive and hypothyroidism and hypoparathyroidism were also diagnosed. She had a daughter with Type 1 (insulin-dependent) diabetes and had a long history of depression with a parasuicidal drug overdose one year previously. She was discharged well on hydrocortisone, alfalcacidol and thyroxine. Three months later she was again admitted with a further Addisonian crisis of no obvious cause. Over the next 4 years she had 14 further admissions, including six Addisonian crises (usually mild), seven episodes with various vague symptoms, and one with depression. Extensive investigations revealed no other pathology apart from unilateral, and apparently asymptomatic, renal calculi. Random plasma cortisol levels both in hospital and clinic were lower (<50 nmol/l) or undetectable despite prescribed doses of oral hydrocortisone up to 60 mg daily (blood samples were taken 1–4 hours after reported morning doses of 20 or 40 mg of hydrocortisone). Thyroid function tests have also suggested under-replacement despite 300 µg thyroxine daily. In addition, serum calcium has been borderline low despite 2 µg alfalcacidol daily. She has consistently denied compliance problems, and intermittent hospitalisations continue.
Discussion

The term ‘brittle’ has been used since the 1940s to describe Type 1 (insulin-dependent) diabetic patients with life-disrupting glycaemic instability and often frequent hospitalisations. The origin of the term is obscure, but it has been ascribed to the American diabetologist Rollin Woodyatt as early as 1940. In relation to asthma, the term was first used in 1977 by Margaret Turner-Warwick in the UK to describe a small sub-group of asthmatic patients with labile and unpredictable airways obstruction. The causes of brittle asthma are uncertain, but psychosocial factors have been implicated in at least some patients. Brittle diabetes has a more established psychogenic and behavioural base, with manipulation of insulin therapy (to induce ketoadosis or hypoglycaemia) thought to be the cause in most cases.

Our two patients with recurrent hypoadrenal crises have striking similarities with these brittle syndromes, in particular brittle diabetes. They were young women (as is common in brittle diabetes, and at least some patients with brittle asthma), and both had frequent (see figure) and unpredictable admissions. Poor compliance with hydrocortisone replacement was also either admitted to or biochemically demonstrated. There were psychosocial disruptions at home, and admission to hospital may have been an escape from difficult home circumstances. Omission of insulin in brittle diabetes can provide a similar ‘gain’ motive by hospitalisation with ketoadosis. There are also parallels with brittle diabetes regarding therapeutic errors, as doctors often respond to recurrent ketoadosis by escalating insulin doses, which may in any case never be taken! Both of our patients were eventually prescribed doses of hydrocortisone and alfacalcidol (for hypoparathyroidism) at least 2–3 times the usual replacement doses. This was despite evidence strongly suggesting poor compliance.

Brittle Addison’s disease is likely to be a further syndrome of maladaptation to a chronic disease that requires lifestyle change and self-treatment. Like brittle diabetes and brittle asthma, its ideal management is uncertain. There is, however, good evidence that the majority of brittle diabetic patients spontaneously resolve with the passage of time, and hopefully the same will be true for brittle Addison’s disease (eg, Case 1). Unfortunately, the game is a dangerous one to play, and whilst brittle diabetes is active, it is associated with excess mortality and morbidity.

Brittle Addison’s disease: a new variation on a familiar theme

Geoffrey V Gill and Gareth Williams

*Postgrad Med J* 2000 76: 166-167
doi: 10.1136/pmj.76.893.166

Updated information and services can be found at:
[http://pmj.bmj.com/content/76/893/166](http://pmj.bmj.com/content/76/893/166)

These include:

**References**

This article cites 5 articles, 1 of which you can access for free at:
[http://pmj.bmj.com/content/76/893/166#BIBL](http://pmj.bmj.com/content/76/893/166#BIBL)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Adrenal disorders (17)
- Diabetes (142)
- Immunology (including allergy) (394)
- Asthma (20)
- Metabolic disorders (221)

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)